<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417012</url>
  </required_header>
  <id_info>
    <org_study_id>U-TURN</org_study_id>
    <nct_id>NCT02417012</nct_id>
  </id_info>
  <brief_title>Lifestyle and Glucose Lowering Medication in T2DM</brief_title>
  <official_title>Does Intensive Life Style Intervention Reduce the Need for Glucose Lowering Medications in Patients With Type 2 Diabetes? The U-TURN Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TRYG Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of a lifestyle intervention maintenance of glycemic control
      while reducing glucose lowering drugs in patients with type 2 diabetes mellitus. The
      intervention group receives an intensive lifestyle intervention including exercise and diet
      lifestyle modifications. The reference group receives diabetes educational advice. Both
      groups will have their pharmacological treatment regulated across the study. The primary
      hypothesis is that lifestyle change is sufficient to maintain glycemic control while
      decreasing the anti-diabetic medication in a sample patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adherence to lifestyle modifications including increased exercise and healthy diet improves
      glycemic control in patients with type 2 diabetes mellitus. However, few have investigated
      the combined effects of these lifestyle changes on maintenance of glycemic control while
      decreasing the usage of anti-diabetic medications.

      The primary hypothesis is that lifestyle change is equivalent in maintaining glycemic control
      (Hba1c) compared to the standard pharmacological treatment,

      The U-TURN trial also tests the effects on one key secondary outcome (glucose lowering
      medication) and examines the effects on sleep quality, fatigue sleepiness, sleep pattern,
      cardio vascular disease risk factors, psychological outcomes, blood pressure and cholesterol
      lowering medication. The participants (N=120) is randomized into a experimental group (N=80)
      and a standard care group (N=40).

      Additionally, the effects of the study will be evaluated 24 month post randomization.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hba1c</measure>
    <time_frame>0, 3, 6, 9, 12 months</time_frame>
    <description>blood sampling of Hba1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glucose lowering medication</measure>
    <time_frame>0, 3, 6, 9, 12 months</time_frame>
    <description>Change in doses of Metformin, GLP-1 analog, insulin. The change will be evaluate according to changes on the pre-specified regulation algorithm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of hypo-glycemic episodes</measure>
    <time_frame>0, 3, 6, 9, 12, 24 months</time_frame>
    <description>Self-report to study nurse</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes Ldl cholesterol</measure>
    <time_frame>0, 3, 6, 9, 12, 24 months</time_frame>
    <description>Blod sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes Hdl cholesterol</measure>
    <time_frame>0, 3, 6, 9, 12, 24 months</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes total cholesterol</measure>
    <time_frame>0, 3, 6, 9, 12, 24 months</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in triglycerides</measure>
    <time_frame>0, 3, 6, 9, 12, 24 months</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in bdnf-a</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in physical fitness</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <description>Progressive treadmill protocol</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in body composition (DXA scan)</measure>
    <time_frame>0, 3, 6, 9, 12, 24 months</time_frame>
    <description>DXA scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in sleep quality</measure>
    <time_frame>0, 12, months</time_frame>
    <description>Self-report using the PSQI questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in sleepiness</measure>
    <time_frame>0, 12, months</time_frame>
    <description>Self-report using the Epsworth questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in sleep pattern</measure>
    <time_frame>0, 12, months</time_frame>
    <description>Cardio-respiratory monitoring</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the degree of depression</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <description>Self-report using the BDI-II questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Glucose tolerance (2-h oral glucose tolerance test)</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <description>2-h oral glucose tolerance test</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Well-being</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <description>Self-report using the questionnaire SF-36 and MFI20</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in motivation for exercise</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <description>Self-report using the questionnaire BREQ-2</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Self-report using the CANTAB test battery</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in arterial function</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Arterial function will be determined using flow mediated dilation in a sub set of N=20 patients in each intervention arm (Total N=20)</description>
  </other_outcome>
  <other_outcome>
    <measure>Partial T2D remission</measure>
    <time_frame>24 months</time_frame>
    <description>No active glucose lowering medication and HbA1c&lt;48 mmol/mol and Fasting blood glucose&lt;6,9 mmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Full T2D remission</measure>
    <time_frame>24 months</time_frame>
    <description>No active glucose lowering medication and HbA1c&lt;39 mmol/mol and Fasting blood glucose&lt;5.6 mmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in low grade inflammation</measure>
    <time_frame>0, 12, 24 months</time_frame>
    <description>The change in pro- and anti inflammatory markers will be evaluated</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>U-TURN intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses.
Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The reference group will receive diabetes education and support by trained nurses.
Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>U-TURN</intervention_name>
    <description>Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated</description>
    <arm_group_label>U-TURN intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Standard individual diabetes support</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Less than three anti-diabetic medications.

          -  Diabetes 2 duration of max 10 years

          -  BMI &gt;25 but &lt;40 kg/m2,

          -  Accept of medical regulation by the UTURN endocrinologists only

          -  Accept of purchasing a fitness club membership through U-TURN collaborator

        Exclusion Criteria:

          -  Hba1c&gt; 9% (75 mmol/mol)

          -  Insulin usage

          -  Presence of one or more of the following micro- and macrovascular complications of
             T2DM; a.Diabetic retinopathy (except mild nonproliferative retinopathy or early
             proliferative retinopathy) b. Macro-albuminuria or nephropathy c. Diabetic neuropathy
             (except mild affected vibratory testing (&lt;50 Volt)) d. Arterial insufficiency e.
             Ischemic heart disease

          -  Steroid treatment (inhalation) until three months before the medical examination

          -  TSH raised/below the normal range

          -  Liver disease (ALAT/ASAT thrice normal range)

          -  Inability or contraindication to increased levels of physical activity (Pedersen BK
             and Saltin B)

          -  Evidence of anaemia

          -  Lung disease (except mild asthma and mild chronic obstructive pulmonary disease)

          -  Heart disease

          -  Kidney disease (creatinine above 130 ÂµM or macro albuminuria)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Ried-Larsen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Physical Activity Research, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports. 2006 Feb;16 Suppl 1:3-63. Review.</citation>
    <PMID>16451303</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Mathias Ried-Larsen</investigator_full_name>
    <investigator_title>Group leader</investigator_title>
  </responsible_party>
  <keyword>lifestyle</keyword>
  <keyword>exercise</keyword>
  <keyword>physical activity</keyword>
  <keyword>diet</keyword>
  <keyword>glycemic control</keyword>
  <keyword>hba1c</keyword>
  <keyword>glucose lowering drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

